Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Gains from Sales and Divestitures (2021 - 2022)

Historic Gains from Sales and Divestitures for TScan Therapeutics (TCRX) over the last 2 years, with Q4 2022 value amounting to $116870.0.

  • TScan Therapeutics' Gains from Sales and Divestitures fell 6363.83% to $116870.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $116870.0, marking a year-over-year decrease of 6363.83%. This contributed to the annual value of $116870.0 for FY2022, which is 6363.83% down from last year.
  • Latest data reveals that TScan Therapeutics reported Gains from Sales and Divestitures of $116870.0 as of Q4 2022, which was down 6363.83% from $321410.0 recorded in Q4 2021.
  • Over the past 5 years, TScan Therapeutics' Gains from Sales and Divestitures peaked at $321410.0 during Q4 2021, and registered a low of $116870.0 during Q4 2022.